Release Candidate definition

Release Candidate means a Sustaining Release or Major Release provided by or for HortonWorks.
Sample 1Sample 2
Release Candidate means the RC Software version with potential to be the FIN Software version, which is ready to release unless significant bugs emerge. The RC Software version may be further modified by the Licensor until the FIN Software version is arrived at. This shall not take longer than until 30 June 2019.
Sample 1Sample 2
Release Candidate means the final version of the program has been approved by the RED MILE, but not yet approved by STRATEGY, as suitable for duplication and shipping. It includes all changes, modifications, alterations, and additions agreed to by STRATEGY and RED MILE based upon review and testing of the Beta Milestone. If approved by STRATEGY, this build becomes the Gold Master. If not approved, the next build is also a Release Candidate with a number designator (Release Candidate 1, Release Candidate 2, etc.)
Sample 1Sample 2

Examples of Release Candidate in a sentence

  • Technical Preview, and Release Candidate versions of the Software, or components within the Software, are considered pre-release software and so may contain defects and errors.

  • The Release Candidate will be then name as the Final Release to be used for deployment purposes.

  • We shall progress an infrastructure build-out environment in parallel with the development tasks so that, at any point it would be possible to package the infrastructure build-out automation and code artefacts into a Release Candidate suitable for a Production environment.

  • The development will go through various Beta Releases, Release Candidate for Acceptance and the Final Release.

  • This task will be completed when the Xxxxxx Mobile Application Release Candidate meets the expected results defined in the Acceptance Test Case Document.

  • Contractor hereby agrees to the following schedule: Release Description Due Date Release 3 Production Release Candidate 1 First Release 3 production release as described in August 6, 2021 Executive Briefing presentation with Release 3 Schedule.

  • Deliverables D10, D20 Numerical Service Initial Beta Version/Release Candidate D22 Service API Release Candidate D15, D21 Symbolic Service Initial Beta Version/Release Candidate D23 Wrapper Tools Release Candidate D25 Mathematical Problem Solving Environment Milestones and expected result The expected results are a set of collaborating services which can be used to solve particular applications.

  • The final Beta release, referred as the Release Candidate for Acceptance, will be used for Acceptance procedure.

  • The official Updates, as described in the Software Releases Overview Section of the XXXX Software License and More website available at xxxxx://xx.xxxx.xxx/licensesmore- igelos11/en (i.e., Major Release, Stable Release, Private Build, and Dead End Release, but excluding Release Candidate and Technology Preview) that are provided to End User pursuant to Support shall be considered XXXX Software under the terms of this XXXX.

Related to Release Candidate

  • continuing candidate means any candidate not deemed to be elected, and not excluded,

  • Independent candidate means any candidate who claims not to be affiliated with a political party, and whose name has been certified on the office-type ballot at a general or special election through the filing of a statement of candidacy and nominating petition, as prescribed in section 3513.257 of the Revised Code.

  • Phase I Study means a study in humans which provides for the first introduction into humans of a product, conducted in healthy volunteers or patients to obtain information on product safety, tolerability, pharmacological activity or pharmacokinetics, as more fully defined in 21 C.F.R. § 312.21(a) (or the non-United States equivalent thereof).

  • Phase I Clinical Trial means a human clinical trial that is intended to initially evaluate the safety and/or pharmacological effect of a Product in subjects or that would otherwise satisfy requirements of 21 C.F.R. 312.21(a), or its foreign equivalent.

  • Licensed Compounds means any EZH2 Compound(s) that is:

  • Exempt compound means the same as defined in Rule 2.

  • Phase III Study means a human clinical trial that is prospectively designed to demonstrate statistically whether a product is safe and effective for use in humans in a manner sufficient to obtain regulatory approval to market such product in patients having the disease or condition being studied as described in 21 C.F.R. § 312.21(c) (FDCA), as amended from time to time, and the foreign equivalent thereof.

  • IND means an Investigational New Drug Application submitted to the FDA in conformance with applicable laws and regulations, or the foreign equivalent of any such application in any other country.

  • Phase II Study means a human clinical trial, for which the primary endpoints include a determination of dose ranges and/or a preliminary determination of efficacy in patients being studied as described in 21 C.F.R. § 312.21(b) (FDCA), as amended from time to time, and the foreign equivalent thereof.